Physician profile
Jay Fuletra
NPI 1295268878
$4,967.10
in general payments reported to CMS, 2019-2025
30 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2021: $89.39 · 2022: $97.65 · 2023: $1,860 · 2024: $1,248 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998 · Education: $1,005 · Travel and Lodging: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,998.26 |
| Education | $1,004.85 |
| Travel and Lodging | $555.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,555.64 | 2023 | Da Vinci Surgical System |
| Procept Biorobotics Corporation | $376.41 | 2024-2025 | Aquabeam System |
| Boston Scientific Corporation | $358.18 | 2019-2024 | Ams 700, Rezum Generator |
| Sumitomo Pharma America, INC. | $350.06 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $219.06 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $215.68 | 2024 | Provenge |
| Immunitybio, INC. | $209.61 | 2025 | |
| Axonics, INC. | $174.16 | 2024 | Axonics |
| Tolmar, INC. | $163.87 | 2023-2025 | Jatenzo, Eligard |
| Merck Sharp & Dohme LLC | $150.20 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $126.46 | 2025 | Xtandi |
| Medtronic, INC. | $115.28 | 2022-2024 | Interstim |
| Myriad Genetic Laboratories, INC. | $98.56 | 2023 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $96.27 | 2024-2025 | |
| Urogen Pharma, INC. | $95.55 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $93.68 | 2023-2025 | Erleada, Akeega, Balversa |
| Novartis Pharmaceuticals Corporation | $88.90 | 2024-2025 | |
| Abbvie INC. | $67.05 | 2024-2025 | |
| Telix Pharmaceuticals | $57.32 | 2023-2025 | Illuccix |
| Calyxo, INC. | $52.74 | 2025 | Cvac Aspiration System |
| Ferring Pharmaceuticals INC. | $52.38 | 2025 | Adstiladrin |
| Dentsply Ih Ab | $37.08 | 2023 | Lofric |
| Ambu INC. | $34.75 | 2024 | |
| Ethicon US, LLC | $31.58 | 2023 | Stratafix, Ethicon |
| Astrazeneca Pharmaceuticals LP | $29.41 | 2023-2025 | Lynparza |
| Teleflex LLC | $28.31 | 2025 | Barrigel |
| Laborie Medical Technologies Corp. | $24.41 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Olympus America INC. | $22.06 | 2025 | Itind System |
| Accord Healthcare, INC. | $21.81 | 2023 | |
| Amgen INC. | $20.63 | 2024 | Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Fuletra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.